CosIng Checker
CosIng Checker
EU cosmetic ingredients, restrictions and safety
Login
Official EU label nameGlossary entry 4210

BUTYRIC ACID

This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.

Global evidence snapshot

The resolved identity has matching regulatory evidence in 0 of 13 indexed market datasets: 0 country records and 0 EU Annex records. Every result and evidence gap is listed below.

0 markets with evidence
Markets checked
13
Markets with evidence
0
Evidence gaps
13
Resolved identifiers
2

A missing local match is not permission, approval or proof of safety. It means no strong identity match was resolved in that indexed dataset.

Resolved substance identity

CAS:107-92-6
EC:203-532-3
Ingredient index records:
BUTYRIC ACID
Cosmetic functions: FRAGRANCE

Butanoic acid

Open full local profile
1 matched or reported name
BUTYRIC ACID

Regulatory evidence in all 13 markets

Open each matched record for its scope, concentration, conditions, warnings and official source version.

Swipe or scroll horizontally to see dataset coverage and next actions.

MarketResultRecordsDatasetMeaning / next action
European Union
EU
No local match0
Complete annex dataset
Regulation (EC) 1223/2009 consolidated to 1 May 2026
No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review.
Great Britain
GB
No local match0
Complete consolidated annex dataset
GB retained Regulation 1223/2009 schedules, effective 15 August 2026
No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.
Canada
CA
No local match0
Complete Hotlist snapshot
Health Canada Cosmetic Ingredient Hotlist, 13 August 2025
The Hotlist is an administrative compliance tool, not an exhaustive safety approval list.
New Zealand
NZ
No local match0
Complete schedules dataset
Cosmetic Products Group Standard schedules effective 1 January 2026
The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative.
ASEAN
ASEAN
No local match0
Complete regional annex dataset
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026
Regional annex coverage does not replace member-state implementation dates, notifications or national deviations.
China
CN
No local match0
Complete prohibited catalogues plus official-source workflow
NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025
IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately.
Japan
JP
No local match0
Complete Standards appendices dataset
MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot
The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion.
South Korea
KR
No local match0
Complete current appendix dataset
MFDS Notice 2026-19, effective 18 March 2026
Korean source wording is canonical and other positive lists/notices may still apply to the formulation.
United States
US
No local match0
Complete enumerated federal ingredient rules
eCFR Title 21 issue date 27 August 2026
FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety.
Australia
AU
No local match0
Complete cosmetic-relevant Poisons Standard subset plus official workflow
Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026
An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction.
Brazil
BR
No local match0
Complete prohibited dataset plus current restricted-list workflow
ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026
RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026.
India
IN
No local match0
Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)
The standards are separate controlled publications; absence from a locally indexed excerpt is not permission.
Saudi Arabia
SA
No local match0
Complete official list index
SFDA live prohibited/restricted lists, snapshot 30 August 2026
No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply.
No market rows match this filter.

Chemical identity and properties

PubChem 2D chemical structure for CAS 107-92-6
CAS 107-92-6PubChem CID 264

Butyric Acid

IUPAC name
butanoic acid
Molecular formula
C4H8O2
Molecular weight
88.11 g/mol
Exact mass
88.052429494 Da
XLogP3
0.8
Topological polar surface area
37.3 Ų
Hydrogen-bond donors
1
Hydrogen-bond acceptors
2
Covalent units
1
Defined stereocentres
0

Also known as

n-Butyric acidn-Butanoic acidpropylformic acidethylacetic acid1-propanecarboxylic acidButanic acid1-Butyric acidButtersaeure
16 more reported names
Kyselina maselnaFEMA No. 2221Propanecarboxylic acid1-butanoic acidFEMA Number 2221Butyricum acidumNORMAL BUTYRIC ACIDNSC-841540UIR9Q29HNSC8415CHEBI:30772Acid, ButanoicTetranoic AcidAcid, ButyricButyrate, Magnesiumfatty acid 4:0
Open full PubChem recordPubChem annotations3D structure image
External database identifiers

Evidence from additional scientific databases

EMBL-EBI ChEBI
Exact identifier matchCHEBI:30772

butyric acid

A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.

Formula
C4H8O2
Average mass
88.106 g/mol
Monoisotopic mass
88.05243 Da
Formal charge
0
  • straight-chain saturated fatty acid — is a (CHEBI:39418)
  • fatty acid 4:0 — is a (CHEBI:140601)
  • Mycoplasma genitalium metabolite — has role (CHEBI:131604)
  • human urinary metabolite — has role (CHEBI:84087)
  • anti-inflammatory agent — has role (CHEBI:67079)
  • Mycoplasma genitalium metabolite — has role (CHEBI:131604)
  • human urinary metabolite — has role (CHEBI:84087)
  • anti-inflammatory agent — has role (CHEBI:67079)
  • straight-chain saturated fatty acid — is a (CHEBI:39418)
  • fatty acid 4:0 — is a (CHEBI:140601)
  • butyrate — is conjugate acid of (CHEBI:17968)
Additional curated names
butanoic acid1-butanoic acid1-butyric acid1-propanecarboxylic acid4:0acide butanoiqueacide butyriquebutanic acidButanoateButanoic acidBUTANOIC ACIDbutoic acidButtersaeurebutyric acidButyric acidButyricum acidumC4:0CH3-[CH2]2-COOHn-butanoic acidn-butyric acidethylacetic acidFEMA NO. 2221Normal butyric acidNSC-8415propanecarboxylic acidpropylformic acid
Cross-references from this source
  • CAS: 107-92-6 — ChemIDplus
  • CAS: 107-92-6 — NIST Chemistry WebBook
  • CAS: 107-92-6 — KEGG COMPOUND
  • REGISTRY_NUMBER: 26242 — Gmelin
  • REGISTRY_NUMBER: 906770 — Reaxys
  • MANUAL_X_REF: BUA — PDBeChem
  • MANUAL_X_REF: Butyric_acid — Wikipedia
  • MANUAL_X_REF: BUTYRIC_ACID — MetaCyc
  • MANUAL_X_REF: C00001180 — KNApSAcK
  • MANUAL_X_REF: C00246 — KEGG COMPOUND
  • MANUAL_X_REF: DB03568 — DrugBank
  • MANUAL_X_REF: HMDB0000039 — HMDB
  • MANUAL_X_REF: LMFA01010004 — LIPID MAPS

Mapped by: Exact CAS cross-reference in the ChEBI compound record. Source updated: 2020-01-23. Retrieved: 2026-08-31. Open source record

NIH PubChem PUG-View
Exact identifier match264

Attributed physical-property, hazard, environmental and use annotations.

  • First Aid: EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.; SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. IMMEDIATELY call a hospital or poison control center even if no symptoms (such as redness or irritation) develop. IMMEDIATELY transport the victim to a hospital for treatment after washing the affected areas.; INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whene Source: CAMEO Chemicals
  • ERG2024, Guide 153 (Butyric acid): General First Aid:; · Call 911 or emergency medical service.; · Ensure that medical personnel are aware of the material(s) involved, take precautions to protect themselves and avoid contamination.; · Move victim to fresh air if it can be done safely.; · Administer oxygen if breathing is difficult.; · If victim is not breathing:; -- DO NOT perform mouth-to-mouth resuscitation; the victim may have ingested or inhaled the substance.; -- If equipped and pulse detected, wash face and mouth, then give artificial respiration using a proper respiratory medical device (bag-valve mask, pocket mask equipped with a one-way valve or other device).; -- If no pulse detected or no respiratory medical device available, provide continuous compressions. Conduct a pulse check every two minutes or monitor for any signs of spontaneous respirations.; · Remove and isolate contaminated clothing and shoes.; · For minor skin contact, avoid spreading material on unaffected skin.; · In case of contact with substance, remove immediately by flushing skin or eyes with running water for at least 20 minutes.; · For severe burns, immediate medical attention is required.; · Effects of exposure (inhalation, ingestion, Source: Emergency Response Guidebook (ERG)
  • Signal: Danger Source: Regulation (EC) No 1272/2008 of the European Parliament and of the Council
  • GHS Hazard Statements: H314: Causes severe skin burns and eye damage [Danger Skin corrosion/irritation] Source: Regulation (EC) No 1272/2008 of the European Parliament and of the Council
  • Precautionary Statement Codes: P260, P264, P280, P301+P330+P331, P302+P361+P354, P304+P340, P305+P354+P338, P316, P321, P363, P405, and P501 (click each P-code to see the statement) Source: Regulation (EC) No 1272/2008 of the European Parliament and of the Council
  • Signal: Danger Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (15.5%): Harmful if swallowed [Warning Acute toxicity, oral]; H314 (99%): Causes severe skin burns and eye damage [Danger Skin corrosion/irritation]; H318 (14.2%): Causes serious eye damage [Danger Serious eye damage/eye irritation] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P260, P264, P264+P265, P270, P280, P301+P317, P301+P330+P331, P302+P361+P354, P304+P340, P305+P354+P338, P316, P317, P321, P330, P363, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 2131 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • Signal: Danger Source: NITE-CMC
  • GHS Hazard Statements: H227: Combustible liquid [Warning Flammable liquids]; H311: Toxic in contact with skin [Danger Acute toxicity, dermal]; H314: Causes severe skin burns and eye damage [Danger Skin corrosion/irritation]; H318: Causes serious eye damage [Danger Serious eye damage/eye irritation]; H371: May cause damage to organs [Warning Specific target organ toxicity, single exposure] Source: NITE-CMC
  • Precautionary Statement Codes: P210, P260, P262, P264, P264+P265, P270, P280, P301+P330+P331, P302+P352, P302+P361+P354, P304+P340, P305+P354+P338, P308+P316, P316, P317, P321, P361+P364, P363, P370+P378, P403, P405, and P501 (click each P-code to see the statement) Source: NITE-CMC
  • Signal: Danger Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • GHS Hazard Statements: H314: Causes severe skin burns and eye damage [Danger Skin corrosion/irritation] Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • Health Effects: Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, incre Source: Toxin and Toxin Target Database (T3DB)
  • NFPA Health Rating: 3 - Materials that, under emergency conditions, can cause serious or permanent injury. Source: Hazardous Substances Data Bank (HSDB)
  • NFPA Fire Rating: 2 - Materials that must be moderately heated or exposed to relatively high ambient temperatures before ignition can occur. Materials would not under normal conditions form hazardous atmospheres with air, but under high ambient temperatures or under moderate heating could release vapor in sufficient quantities to produce hazardous atmospheres with air. Source: Hazardous Substances Data Bank (HSDB)
  • NFPA Instability Rating: 0 - Materials that in themselves are normally stable, even under fire conditions. Source: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: Butyric acid is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as a h Source: Toxin and Toxin Target Database (T3DB)
  • Environmental Bioconcentration: An estimated BCF of 3.2 was calculated for n-butanoic acid(SRC), using a log Kow of 0.79(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 64(SRC), determined from a log Kow of 0.79(2) and a regression-derived equation(3), and experimental values of 19.1, 27.6, and 14.7 in mud, muddy sand, and sand(4), indicate that n-butanoic acid is expected to have very high to high mobility in soil(SRC). The pKa of n-butanoic acid is 4.82(5), indicating that this compound will primarily exist in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(6). Volatilization of butyric acid from moist soil surfaces is expected to be slow(SRC) given a Henry's Law constant of 5.35X10-7 atm-cu m/mole(7). n-Butanoic acid is expected to volatilize from dry soil surfaces(SRC) based upon a vapor pressure of 1.65 mm Hg(8). N-butanoic acid may be susceptible to biodegradation in terrestrial environments based on the observed degradation of 72% after 5 hours when incubated with activated sludge(9,10). Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), experimental Koc values of 19.1, 27.6, and 14.7 on a clastic mud (3.5% organic carbon), a lateritic muddy sand (1.3% organic carbon), and a fine carbonate sand (0.17% organic carbon), respectively(2), indicate that n-butanoic acid is not expected to adsorb to suspended solids and sediment(SRC). The pKa of n-butanoic acid is 4.82(5), indicating that this compound will primarily exist in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(6). Volatilization from water surfaces is expected to be slow(3) based upon a Henry's Law constant of 5.35X10-7 atm-cu m/mole(4). Using this Henry's Law constant and an estimation method(3), volatilization half-lives for a model river and model lake are 64 and 471 days, respectively(SRC). According to a classification scheme(7), an estimated BCF of 3.2(SRC), from a log Kow of 0.79(8) and a regression-derived equation(9), suggests the potential for bioconcentration in aquatic organisms is low(SRC). n-Butanoic acid may be susceptible to biodegradation in aquatic environments based on the observed Source: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), n-butanoic acid, which has a vapor pressure of 1.65 mm Hg at 25 °C(2), is expected to exist solely as a vapor in the ambient atmosphere. Vapor-phase butyric acid is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 7 days(SRC), calculated from its rate constant of 2.40X10-12 cu cm/molecule-sec at 25 °C(3). n-Butanoic acid does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight(4). Source: Hazardous Substances Data Bank (HSDB)

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
EMBL-EBI ChEBIExact match2026-08-31
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Additional authoritative substance research

These source-specific lookups can add hazard, toxicology, identity and assessment context. A link is a research route, not a claim that the source contains an exact record.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Research this identity

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Research this identity

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Research this identity

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Research this identity

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Research this identity

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Research this identity

US EPA CompTox CTX APIs

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Research this identity

Continue the compliance check

1. Confirm identity

Match the supplier specification, CAS/EC identifiers and composition to this official label name. Similar wording is not proof of chemical equivalence.

2. Review restrictions

Check every exact Annex record shown above, plus CMR, nanomaterial, SCCS and later-amendment requirements that may apply.

3. Verify the formula

Evaluate concentration, product type, purity, warnings, claims and each target market before making a compliance decision.

Screen in a formulaOpen standalone comparison

Official source and scope

Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.

Open official Decision